ImmunityBio Climbs 6.8% on Light Trading as Analysts See Moderate Buy
ImmunityBio shares rose 6.8% to about $10.58, though trading volume was far below the stock's average. Analysts have a Moderate Buy consensus and a $14.20 average price target, even with one sell rating still in place. The company reported a quarterly loss of $0.22 per share, missing estimates, while revenue of $51.24 million beat expectations; two directors also sold shares under prearranged plans.
ImmunityBio's Friday gain lifted shares to roughly $10.58 after a prior close of $9.91. Volume reached 995,368, about 95% below its usual 20.57 million. Analysts split: one Strong Buy, five Buy, one Sell, yielding Moderate Buy and a $14.20 target. The company's market value was $11.07 billion; 50- and 200-day averages stood at $8.25 and $7.88.
Quarterly results showed a $0.22 per-share loss, $0.14 wider than expected, while $51.24 million revenue topped the $49.70 million consensus. Two directors sold under Rule 10b5-1 plans; insiders own 66.10%.
ImmunityBio's jump may matter most to shareholders, including insiders and institutions, whose holdings can swing with thin volume. For patients and providers, the company's access to capital and research momentum could indirectly affect future treatment options, though one session's price move does not determine clinical or commercial outcomes. Analysts' mixed ratings and insider sales may shape confidence, while broader biotech investors could read the episode as a reminder of volatility and the limits of short-term market signals.